Sanofi: Decent quarterly report and reassuring guidance for 2016

NEUTRAL, Fair Value EUR90 (+29%)
News published on February Tuesday 9, 2016
Share on

As Sanofi is entering a two-year transition phase with “no meaningful growth”, it is fairly reassuring that the group is able to deliver in-line core EPS numbers for 2015 on which base it has formed guidance for “broadly stable” figures for 2016. This is obviously not bad at all as Q4 2015 final numbers included very high vaccines sales and a very low tax rate of 19.5%. Although share buybacks are set to make a very significant contribution (EUR1bn bought back in January alone), this should make it possible to deliver core EPS in the region of EUR5.50 once negative currency impacts are factored in i.e. only 1-2% below current consensus estimates but above ours.

For more information, please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities